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A B S T R A C T
Purpose
Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50
years old or younger. We sought to determine whether young age is prognostic, or whether it
influences efficacy/toxicity of chemotherapy, in patients with advanced disease.
Methods
We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal
cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End
points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade
3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to
test for age effects and age-treatment interactions.
Results
A total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total
patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P  .01) was more
common, and severe diarrhea (11% v 14%; P  .001) and neutropenia (23% v 26%; P  .001)
were less common in young (younger than 50 years) than in older (older than 50 years) patients.
Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years
(median, 6.0 v 7.5 months; hazard ratio, 1.10; P  .02), but it did not affect RR or OS. In the subset
of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent
chemotherapy were similar for young and older patients. Results were comparable when utilizing
an age cut point of 40 years.
Conclusion
Young age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC,
and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in
general. Young versus older patients derive the same benefits from combination chemotherapy.
Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate
for young patients with aCRC.
J Clin Oncol 29:2781-2786. © 2011 by American Society of Clinical Oncology
INTRODUCTION
The 2010 estimates in the United States identified
142,570 new occurrences of colorectal cancer and
51,370 deaths as a result of that malignancy.1 Colo-
rectal cancer is predominantly a disease of the el-
derly; the median age is 72 years, and 28% of patients
are older than 80 years.2,3 A higher proportion of
older patients present with locoregional disease.4
Treatment does benefit at least some older patients;
indeed, fit elderly with advanced colorectal cancer
(aCRC) experience approximately the same benefits
from systemic therapy as those in the more common
age demographics.5
In young patients, colorectal cancer tends to
present more commonly with stage III or IV dis-
ease.6 Stage for stage, the prognosis is similar in
younger patients, though overall survival (OS) is
clearly worse in the youngest subgroups. The predic-
tive effect of younger age as related to systemic ther-
apy, especially with newer agents, is unknown.
Because of an inherited defect in DNA mismatch
repair (Lynch syndrome), young patients tend to
have a higher proportion of tumors demonstrating
microsatellite instability, which are associated with a
better prognosis but which may predict for lower
benefit from fluorouracil-based chemotherapy, at
least in the adjuvant setting.7,8
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We studied a number of phase III chemotherapy trials in patients
with aCRC, assessing outcomes in younger versus older patients.
Herein, we describe analyses of the pooled results of nine randomized
trials and subsets of those treated with oxaliplatin- and irinotecan-
containing regimens. We also looked specifically at monotherapy
versus combination chemotherapy (in a subset of the randomized
trials) in the young and older patients to gauge potential differential
treatment effects.
METHODS
The Adolescent and Young Adult Oncology Progress Review group, funded by
the National Institutes of Health in conjunction with the Livestrong Founda-
tion, recommended a systematic review of available clinical trials data, origi-
nally aiming to determine whether there were biologic and/or outcome
differences according to age in select common cancers (including colorectal
neoplasms). They approached authors of large-scale randomized trials that
were expected to harbor significant numbers of young patients, ages 15 to 39
years. When colorectal cancer was determined to be of interest, nine studies
testing fluorouracil-based chemotherapy in advanced disease were selected for
additional analysis on the basis of data availability and relevance to current
practice. Details regarding the individual clinical trials and patient character-
istics are listed in Appendix Table A1 (online only).9-17 The individual trials
were approved by local investigational review boards at the time the studies
were conducted, and our pooled analyses were approved by the Mayo Clinic
investigational review board.
The principle investigators of the trial supplied individual patient data.
Cox proportional hazards models stratified by study, and logistic-regression
models adjusting for trial, were used to test for age effects using two prespeci-
fied cut points: age younger than 40 years versus 40 years or older and age
younger than 50 years versus 50 years or older.18,19 Age by treatment interac-
tions were assessed as well by using a likelihood ratio test. Objective response
rates (RRs), progression-free survival (PFS), and OS were compared by using
data from all nine trials, as were rates of grade 3 or greater adverse events (by
using National Cancer Institute Common Toxicity Criteria, version 2.020).
These analyses were subsequently conducted in the eight trial-specific treat-
ment arms that contained a fluoropyrimidine and oxaliplatin regimen. A
similar analysis was also performed on the six treatment arms that consisted of
a fluoropyrimidine/irinotecan combination. Finally, to gauge the relative ben-
efit of multidrug chemotherapy in the two age groups, similar efficacy analyses
were carried out in the subset of five trials comparing monotherapy to combi-
nation chemotherapy. Details of the oxaliplatin- and irinotecan-containing
trials, as well as those included in the combination chemotherapy analyses, are
supplied online. All analyses were carried out with the Linux release of SAS,
version 9.2 (SAS Institute, Cary, NC); P values reported are two sided, and P
values less than .05 denote statistical significance.
RESULTS
The nine trials included in the primary analyses were conducted from
August 1995 to August 2004, and they included 6,286 patients. Two
patients were missing age data, so 6,284 were eligible for our analyses.
One hundred eighty-eight (3% of patients) were younger than age 40
years, and 793 (13%) were younger than age 50 years (Appendix Table
A2, online only). Two thousand, one hundred fifty-three patients were
treated with oxaliplatin-containing chemotherapy, of whom 2% were
younger than 40 years of age and 11% were younger than 50 years of
age (Appendix Tables A3 and A4, online only). One thousand, four
hundred ninety-five patients received irinotecan-containing therapy,
of whom 4% were younger than 40 years of age and 16% were younger
than 50 years of age (Appendix Tables A5 and A6, online only).
Toxicity
All trials. Patients younger than 40 years versus those 40 years or
older had more grade 3 or worse nausea (14% v 7%; odds ratio [OR],
1.74; P  .01) but less neutropenia (26% v 26%; OR, 0.67; P  .03;
Table 1). Rates of diarrhea and stomatitis were similar between the two
age groups. When comparing those patients younger than 50 years to
those 50 years or older, younger patients had more nausea (10% v 7%;
OR, 1.38; P  .01) but less diarrhea (11% v 14%; OR, 0.68; P  .001)
and neutropenia (23% v 26%; OR, 0.64; P  .001). Rates of stomatitis
were similar between age groups.
Oxaliplatin-Containing Arms
When assessing just those treatment arms containing oxaliplatin,
no significant differences were seen in grade 3 or worse adverse event
rates comparing either age group to older patients (Appendix Table
A7, online only). Patients younger than 50 years had borderline in-
creased rates of nausea compared with those age 50 years or older
(10% v 6%; OR, 1.59; P  .06).
Irinotecan-Containing Arms
When a similar subset analysis was carried out to evaluate treat-
ment arms containing irinotecan and fluorouracil regimens, no sig-
nificant differences were seen in grade 3 or worse adverse event rates
when comparing patients younger than 40 years with those age 40
years or older (Appendix Table A8, online only). Patients younger
than 50 years, however, had lower rates of diarrhea (16% v 22%; OR,
0.58; P  .006) and neutropenia (29% v 36%; OR, 0.62; P  .006) than
did those age 50 years or older.
Efficacy
All trials. RRs were virtually identical when comparing patients
younger than 40 years of age to those age 40 years or older (41% v 43%;
OR, 1.01; P  .96) and those younger than 50 years to those age 50
years or older (42% v 43%; OR, 1.02; P .84). The median PFS did not
significantly differ for patients age younger than 40 years and those 40
years or older (5.9 v 7.4 months; hazard ratio [HR], 1.05; P  .54; Fig
1A). The median PFS was worse when comparing patients younger
Table 1. Grade 3 or Worse Toxicity Rates in All Trials




Young Old OR 95% CI P 
Younger than 40 years v
40 years or older
Nausea 14 7 1.74 1.13 to 2.69 .01
Vomiting 15 6 2.23 1.45 to 3.43  .001
Diarrhea 12 14 0.71 0.46 to 1.12 .14
Stomatitis 1 2 0.51 0.12 to 2.10 .35
Neutropenia 26 26 0.67 0.47 to 0.96 .03
Younger than 50 years v
50 years or older
Nausea 10 7 1.38 1.07 to 1.78 .01
Vomiting 9 6 1.33 1.00 to 1.77 .05
Diarrhea 11 14 0.68 0.54 to 0.86 .001
Stomatitis 2 2 0.85 0.48 to 1.50 .57
Neutropenia 23 26 0.64 0.53 to 0.78  .001
Multivariate P value from logistic regression adjusted for trial.
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than 50 years to those age 50 years or older (6.0 v 7.5 months; HR, 1.10;
P .02; Fig 1B). The median OS did not differ in the cohort of patients
younger than 40 years versus those age 40 years or older (16.2 v 16.5
months; HR, 1.04; P  .61; Fig 2A) or in those younger than 50
years versus those age 50 years or older (15.8 v 16.6 months.; HR,
1.03; P  .48; Fig 2B).
Oxaliplatin-Containing Arms
The RRs were numerically lower in patients who were younger
than 40 years or age compared with those age 40 years or older, though
the difference was not statistically significant (41% v 56%: OR, 0.58;
P  .08). The RRs were similar for patients younger than 50 years or
age versus those age 50 years or older (54% v 56%; OR, 0.94; P  .66).
The median PFS was shorter for those patients younger than 40 years
compared with those age 40 years or older (6.7 v 8.6 months; HR, 1.36;
P  .05; Appendix Fig A1A, online only). The PFS in patients younger
than 50 years or age versus those 50 years or older and the OS in both
cohorts comparing young versus older ages did not differ (Appendix
Figs A1B, A2A, and A2B, online only).
Irinotecan-Containing Arms
The RRs were comparable in young versus older patients for both
age cut points of 40 years (45 v 46%; OR, 1.06; P  .83) and 50 years
(48 v 46%; OR, 1.16; P  .31). The PFS and OS did not significantly
different in young versus old patients when using either age cut point
(survival curves not shown).
Monotherapy Versus Combination
Chemotherapy Subset
We repeated our previous analyses in the subset of five trials that
tested fluorouracil-based monotherapy and combinations of oxalip-
latin or irinotecan with fluorouracil. The RR for monotherapy versus
combination chemotherapy in patients younger than 40 years were
31% and 51%, respectively (OR, 2.79; 95% CI, 1.13 to 6.90; Table 2).
The RR for the same comparison in patients age 40 years and older
were 29% and 51%, respectively (OR, 2.69; 95% CI, 2.33 to 3.11). No
evidence of an age-by-chemotherapy interaction emerged (P  .78),
providing evidence that younger and older patients did not receive
differential benefit from combination therapy in terms of RR. The RR
for monotherapy versus combination chemotherapy in those patients
younger than 50 years were 28% and 54%, respectively (OR, 3.29; 95%
CI 2.18 to 4.96; Appendix Table A9, online only); the RR for the same
comparison in those age 50 years or older were 29% and 51%, respec-
tively (OR, 2.63; 95% CI 2.26 to 3.06). The age-by-chemotherapy
interaction was again not significant, for which P  .43.
The median PFS for monotherapy versus combination chemo-




















































Fig 1. Progression-free survival in all trials (N  6,284). (A) Younger than 40











































Fig 2. Overall survival in all trials (N  6,284). (A) Younger than 40 years old
versus 40 years or older. (B) Younger than 50 years old versus 50 years or older.
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years (HR, 0.70; 95% CI 0.45 to 1.08) and 6.1 versus 8.3 months in
those age 40 years or older (HR, 0.73; 95% CI, 0.68 to 0.78; Figs 3A and
3B). For the test for an age-by-chemotherapy interaction, P  .69. The
median PFS for monotherapy versus combination chemotherapy was
4.7 versus 7.2 months in those younger than 50 years (HR, 0.64; 95%
CI, 0.52 to 0.78) and 6.2 versus 8.4 months in those age 50 years or
older (HR, 0.74; 95% CI, 0.69 to 0.80; Appendix Fig A3A and A3B,
online only). For the age-by-treatment interaction, P  .11, which
provided no evidence that younger patients received less PFS benefit
from combination chemotherapy than did older patients.
The median OS for monotherapy versus combination chemo-
therapy was 13.3 versus 15 months in those patients younger than 40
years (HR, 0.95; 95% CI, 0.62 to 1.47) and 14.7 versus 16.6 months in
those age 40 years or older (HR, 0.87; 95% CI, 0.81 to 0.94; Figs 4A and
4B). For the age-by-chemotherapy interaction, P  .84. The median
OS for monotherapy versus combination chemotherapy was 13.5





Younger Than 40 Years 40 Years or Older
Mono Combo HR/OR† 95% CI P Mono Combo HR/OR† 95% CI P
Median PFS, months 4.7 6.5 0.70 0.45 to 1.08 .10 6.1 8.3 0.73 0.68 to 0.78  .001 .69
Median OS, months 13.3 15.0 0.95 0.62 to 1.47 .82 14.7 16.6 0.87 0.81 to 0.94  .001 .84
RR, % 31 51 2.79 1.13 to 6.90 .03 29 51 2.69 2.33 to 3.11  .001 .78
Abbreviations: Mono, monotherapy; combo, combination therapy; HR, hazard ratio; OR, odds ratio; PFS, progression-free survival; OS, overall survival; RR,
response rate.
P value testing for age by chemotherapy interaction.




















































Fig 3. Relative treatment benefit (ie, progression-free survival) in five mono-
therapy versus combination chemotherapy trials (N  3,813). (A) Younger than 40










































Fig 4. Relative treatment benefit (ie, overall survival) in five monotherapy versus
combination chemotherapy trials (N  3,813). (A) Younger than 40 years old. (B)
Forty years or older.
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versus 16.3 months in those patients younger than 50 years (HR, 0.82;
95% CI, 0.67 to 1.02) and 14.8 versus 16.5 months in those patients age
50 years or older (HR, 0.89; 95% CI, 0.82 to 0.96; Appendix Figs A4A
and A4B, online only). Testing for an age-by-chemotherapy interac-
tion yielded P  .57, which provided no evidence of a differential level
of OS benefit of combination therapy in patients younger than 40 or
younger than 50 years.
DISCUSSION
Although rare in young adults, colorectal cancer can occur before age
40 years, and the incidence in the younger population has increased
recently, whereas it has remained fairly flat or has declined modestly in
those of more elderly age.3 Questions have been raised as to whether
the biology of the disease is different in the young—specifically,
whether the disease is inherently more aggressive, as well as whether
the young respond differently to systemic therapy. Outcomes for
adolescents and young adults with a variety of cancer types are worse,
but usually these data apply to pediatric tumors (eg, sarcomas, leuke-
mias) that affect a slightly older than usual population. In general,
epithelial neoplasms have not been well studied.21,22 Young patients
with colorectal cancers tend to present at a more advanced stage (the
majority at stage III or worse), which may reflect differing biology but
which might also be explained by differing practice patterns before
diagnosis according to the age of the patient (eg, elderly general pop-
ulation patients might be more likely to get screening colonoscopies,
rectal exams, or stool guiac testing compared with younger patients).
Stage-adjusted outcomes tend to be similar in the young versus
older patients.6
Inherited syndromes, such as familial adenomatous polyposis
and hereditary nonpolyposis colorectal cancer (HNPCC), are more
common in the young, and at least HNPCCs tend to behave less
aggressively, in that those with HNPCC-associated aCRCs have better
survival.7 The impact of potentially associated genetic factors compli-
cates matters. Microsatellite instability (MSI) is a hallmark of
HNPCCs,andrecentdatahavesuggestedthatfluorouracil-basedchem-
otherapy does not benefit patients with high-MSI tumors.7,8 However,
the majority of these data were derived from patients in the adjuvant
setting. The effect on patients with metastatic disease, especially when
fluorouracil is also combined with modern drugs, is difficult to dis-
cern. There is a paucity of information regarding regimens that con-
tain oxaliplatin, and some limited data suggest that MSI (not
necessarily related to age) is a positive predictor of response to
irinotecan-based regimens (data also derived from the adjuvant set-
ting).23 The percentage of patients with high-MSI disease on our study
is not known; regardless, inherited syndromes still only account for a
small fraction of large bowel neoplasms in the young.
Other important questions are whether or not young patients are
well represented on clinical trials and, indirectly, whether trial results
apply to the young population. Bleyer et al22 suggested that the lack of
improvement in outcomes for the adolescent and young adult popu-
lation over the last 40 years may relate to lower rates of participation in
clinical studies.22 Patients age 50 years or younger represented 13% of
all the patients entered onto the aCRC trials we studied. In the general
population, patients younger than 50 years of age comprise only 4.6%
of those with colorectal cancer3; thus, if anything, younger patients
were over-represented in the individual studies and on our study as a
whole. Although this could reflect the more advanced stage at presen-
tation of adolescent and young adult patients with CRC, similar pat-
terns have been observed in adjuvant colorectal cancer trials (Sargent
et al, manuscript in preparation). This suggests that the lower rates of
participation by adolescent and young adult patients with pediatric
cancers in clinical trials are not recapitulated in clinical studies of adult
cancers. The subtype-specific dependence on trial participation may
reflect the fact that adolescent and young adult patients are over-
whelmingly treated in adult cancer settings as well as reflect the rela-
tively poor penetration of this market by pediatric trials compared
with adult studies. It is also interesting to speculate whether the age-
dependent disparity in outcomes for adolescents and young adults
with colorectal cancer relative to pediatric cancers (stage for stage) is
related to the relatively good participation of adolescent and young
adult patients of in trials of the former but not in the latter.
In our analyses, younger and older patients in general had similar
outcomes. RRs, PFS, and OS did not significantly differ for those
younger than 40 years compared with those age 40 years or older. RR
and OS were similar in those younger than 50 years and those age 50
years or older; PFS was minimally worse in the younger cohort (6.0 v
7.5 months; P  .02), which was likely a spurious finding arising from
chance alone. When assessing oxaliplatin-containing chemotherapy
in those younger than 40 years compared with those age 40 years or
older and in those younger than 50 years versus those age 50 years or
older, the only efficacy parameter that differed was PFS, which was
shorter in the patients younger than 40 years of age (6.7 v 8.6 months
in those age 40 years or older; P  .05). Given the large number of
comparisons made, it is quite possible that these two significant find-
ings were also a result of chance. The demonstration that OS did not
significantly differ in any age comparison also minimizes the clinical
relevance of the observed PFS differences. No efficacy differences were
seen by age in assessing the potential effect of irinotecan-containing
systemic therapy. Additionally, it should be noted patients at the
youngest extreme are rare and were not well represented, even on
our study.
Toxicity patterns varied mildly by age. The youngest (younger
than 40 years of age) had more nausea but less neutropenia than older
patients; those younger than 50 years, compared with those age 50
years or older, had similar patterns of relative toxicity as well as less
diarrhea. No differences in the various age groups were seen when
specifically assessing oxaliplatin-containing chemotherapy. In assess-
ing the irinotecan-containing arms, patients younger than 50 years of
age had less diarrhea and neutropenia than did those age 50 years and
older. Other chemotherapy trials have shown higher rates of vomiting,
diarrhea, and dehydration in elderly patients who received the irino-
tecan, bolus fluorouracil, and leucovorin regimen12; with oxaliplatin-
based chemotherapy, the elderly experience more neutropenia and
thrombocytopenia.24 None of the differences we observed were of
sufficient magnitude to influence clinical practice.
A key question is whether younger and older patients receive
different benefits from the newer combination chemotherapy regi-
mens. In our analyses, younger patients derived the same magnitude
of benefit from combination chemotherapy and single-agent treat-
ment. This was manifested by similar levels of improvements in RR,
PFS, and OS in each age group. ORs for response (single-agent v
combinations) and HRs for the comparison of PFS and OS were quite
similar in the patients younger than 40 years of age and those age 40
years or older as well as in the patients younger than 50 years of age and
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those age 50 years or older. Although there was no major differential
effect seen with the regimens utilized in the studies included in our
analysis, it remains possible that younger patients might be fitter and
better able in general to tolerate more intense programs, such as
fluorouracil, oxaliplatin, and irinotecan.25 This could, theoretically,
lead to better outcomes in younger patients.
In summary, this pooled analysis has demonstrated that younger
age is not associated with meaningfully poorer outcomes in patients
with aCRC. Younger patients also derive the same level of benefit from
combination chemotherapy. Toxicity patterns do not vary sufficiently
to change therapeutic recommendations on the basis of patient age.
Young adult participation rates in aCRC clinical trials appears better
than those seen in patients with pediatric cancer types, but only a small
fraction of those with aCRC enter onto studies. In the absence of an
applicable clinical trial, combination chemotherapy remains the ap-
propriate standard of care for younger patients with aCRC.
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